The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
|
|
- Lewis George
- 8 years ago
- Views:
Transcription
1 Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD Professor of Radiology The Perelman School of Medicine University of Pennsylvania SRU 214 Thyroid Cancer and FNA Thyroid Cancer Each thyroid nodule is either a cancer or not a cancer Thyroid FNA is the best non surgical diagnostic tool to diagnose malignancy Thyroid FNA is not always able to distinguish a cancer from a non cancerous lesion, only surgical pathology is able to make that distinction Thyroid Epithelial Tumors are derived from follicular cells (95% of all cancers) Well differentiated Papillary Cancer (8%) Pure papillary cancer Follicular Variant of Papillary cancer Well differentiated Follicular Cancer (1%) Poorly differentiated Papillary Cancer (5%) Anaplastic Cancer ( < 1%) Medullary cancers are derived from parafollicular or C cells (3 to 5%) Pure Follicular Cancers 1% of all thyroid cancers in the US; higher in iodine deficient areas female > male; peak in 6th decade 87% ten year survival (c/w 99% for PTC) Histologically similar to the benign follicular adenoma but demonstrates capsular invasion on surgical pathology Of all follicular tumors, 8% benign adenoma and 2% carcinoma Follicular cancer Capsular invasion Vascular invasion 1
2 Thyroid FNA Benign = heterogeneous population of follicular cells, no atypical nuclear features, often colloid and macrophages Malignant = papillary tissue fragments, abnormal nuclear features such as irregular contours and nuclear grooves, intranuclear cytoplasmic inclusions, usually indicates a papillary cancer Thyroid FNA Non diagnostic = insufficient number of cells to render a definite diagnosis (adequacy often defined as 6 to 8 groups of cells, each group of at least 1 cells) Indeterminate = monotonous follicular cells without abnormal nuclear features DDX: benign follicular adenoma, pure follicular cancer, follicular variant of papillary thyroid carcinoma, benign hyperplastic nodule, focal area of chronic lymphocytic thyroiditis Thyroid FNA and Risk for Cancer Benign 6 7% of FNAs 96+ % benign Non diagnostic 2 1% of FNAs Risk of cancer 1 to 1% Indeterminate 2 3% of FNAs 15 75% cancer risk Papanicolaou Society of Cytopathology Task Force on Standards of Practice, 1997 Malignant 5 15% of FNAs 99+% malignant Standard of care for Indeterminate Thyroid Lobectomy (majority of patients) With completion thyroidectomy if malignant histology, about 15 to 2% Up to 85% unnecessary surgeries for benign disease Surgical risk of permanent hypoparathyroidism and RLN injury (1 to 2 %) Total thyroidectomy if high risk history, bilateral nodules, patient preference, cytologic features FNA Benign Non diagnostic Indeterminate FLUS or AUS Neoplasm Atypia of uncertain significance Malignant Suspicious for Malignancy Baloch ZW et al, Diagnostic Cytopath 28 Malignancy risk Nondiagnostic or unsatisfactory ~1-5% Benign 2-4% Atypia or follicular lesion of 5-15% unknown significance (AUS/FLUS) Follicular neoplasm 15-3% Suspicious for malignancy 6-75% Malignant 97-1% Baloch ZW, Diag Cytopath 36:425, 28; Wang Thyroid :243 2
3 BETHESDA Malignancy risk Management Nondiagnostic or ~1-5% Repeat FNA unsatisfactory Benign 2-4% Observe with US Follow up Malignant 97-1% Total Thyd Atypia or follicular lesion of unknown significance (AUS/FLUS) BETHESDA Malignancy risk 5-15% Follicular neoplasm 15-3% Suspicious for malignancy 6-75% Management Repeat FNA ATYPIA/FOLLICULAR LESION OF UNDETERMINED SIGNFICIANCE (AUS/FLUS) Frequency (%) Repeat FNA cytology in FLUS/AUS nodules 5% Benign 15% sptc AUS/FLUS on Second FNA BETHESDA Malignancy risk? Higher than 5-15% Management Surgery vs observation Follicular neoplasm 15-3%?? Hemi Thyd Suspicious for malignancy 6-75%? Total vs Hemi- Thyd Benign FLUS/AUS Foll Neo Susp PTC/PTC Baloch, Diagn Cytopathol 23; Yassa Cancer 27 Testing Beyond : Additional Testing for Indeterminate FNA Results Genetic analysis Single Oncogene (BRAF) Oncogene mutation panels (Asuragen TM ) RNA Expression Micro RNA Afirma TM gene expression classifier Testing Beyond : Additional Testing for Indeterminate FNA Results Goal is to better predict malignancy in patients having thyroid surgery and perform total thyroidectomy for indeterminate nodules with very high chance of cancer Goal is to better predict benignity to avoid surgery for the management of indeterminate nodules with a low chance of malignancy 3
4 Oncogene Analysis: Point Mutations and Chromosomal Rearrangements BRAF Mutations in 347 Thyroid Nodules: Prevalence and Specificity PAX8/PPAR Number of cases reported Benign Nodules BRAF V6E 1 (.16%) Follicular Carcinoma Papillary Carcinoma PDC and AC % (3-83%) 21% (-5%) Meta analysis of literature Nikiforov Nature Rev Endocrinol 211 7:569 Nikiforov Nature Rev Endocrinol 211 7:569 PTC with Oncogenes (7%) PAX8/PPAR 1-5% Specificity (%) Mutation panel (BRAF, RAS, RET/PTC, PPAR ) HIGH specificity Nikiforov (n=513) Cantara (n=95) Moses (n=137) Follicular neoplasm Susp for malignancy FLUS Nikiforov J Clin Endocrinol Metab :339; Cantara J Clin Endocrinol Metab 21 95:1365; Moses W J Surg 21 34:2589 Sensitivity (%) Mutation panel (BRAF, RAS, RET/PTC, PPAR ) NOT optimal sensitivity Nikiforov (n=513) Cantara (n=95) Moses (n=137) Many cancers are not positive Follicular neoplasm Susp for malignancy FLUS Nikiforov J Clin Endocrinol Metab :339; Cantara J Clin Endocrinol Metab 21 95:1365; Moses W J Surg 21 34: % 2 13% FA RAS HRAS, NRAS codon 61 KRAS codons 12,13 PAX8/PPAR FA Overlap of Follicular Adenoma and CA 4% 3% FC FC ~7% Follicular CA 4
5 BRAF RET/PTC PPAR RAS 1% CANCER False positives Proposed Algorithm by Endocrine Society 45 4 Nikiforov n=61 Cantara n=13 Moses n= RAS False positive rate Nikiforov J Clin Endocrinol Metab :339; Cantara J Clin Endocrinol Metab 21 95:1365; Moses W J Surg 21 34:2589 Frequency (%) 211 by Endocrine Society Nikiforov Y E et al. JCEM 211;96: Mutation panel (BRAF, RAS, RET/PTC, PPAR ) Should not use to AVOID surgery if the test is negative not optimal sensitivity you will miss cancers When a patient is going to surgery, you want a test to optimize the surgical procedure High specificity high positive predictive value Refer patients with cytology of suspicious for PTC who test positive for the Oncogene panel for total thyroidectomy instead of hemi thyroidectomy Malignancies with FN and FLUS less likely to be mutation positive than sptc 1 Yip J Clin Endocrinol Metab :195 When do we use Oncogene Panel testing at Penn? suspicious for malignancy Nodule with follicular neoplasm or FLUSx2 cytology when observation is NOT felt to be an option Large nodules >3cm Suspicious sonographic features? Non diagnostic cytology x 2 Cantara et al: 14/53 nodules with nondx cytology had mutations 12 cancers Cantara J Clin Endocrinol Metab 21 95:1365 Testing Beyond : Additional testing for Indeterminate FNA Results Oncogene testing BRAF Oncogene mutation panels (Asuragen TM ) RNA Expression Micro RNA Afirma TM gene expression classifier Hypothesis of GEC A novel, molecular diagnostic test could be developed with high Negative Predictive Value (NPV) for malignancy. When applied to cytologically indeterminate thyroid nodules, a benign gene expression classifier (GEC) result would accurately predict a non cancerous nodule. 5
6 Development of a gene expression classifier (GEC) to accurately identify benign thyroid nodules in patients with indeterminate FNA cytology AFIRMA DEVELOPMENT Whole Transcriptome approach using microarray technology Molecular Classifier Trained and Validated to Distinguish Benign vs. Suspicious Nodules Feasibility Development Validation On Whole Genome Exon Array, went from 22K to 3K genes relevant to thyroid neoplasia From 3K set, selected final 142 genes and locked final algorithm Tested final 167 gene expression classifier on independent samples A multidimensional algorithm required to separate complex data sets Benign Number of Genes 22K genes 3K genes 167 genes Suspicious Chudova D, et al. J Clin Endocrinol Metab Results by Cytopathology Diagnosis N/A N (sample size) = N Engl J Med :26 Alexander EK, et al. NEJM 212. Non-diagnostic or unsatisfactory Malignancy risk Management ~1-5% Repeat FNA Benign 2-4% Observe with US Follow up Afirma in action 51 endocrinologists surveyed 9/11-3/ pts with indeterminate cytology and benign GEC Pattern of surgical referral evaluated FLUS x 2 GEC Negative FN in low risk patient 5-6% Observe with US Follow up % recommended for surgery p<.1 8 With benign GEC 74 Traditional paradigm Duick Thyroid :996; Wang Thyroid :243 6
7 Afirma TM in action Mayo clinic US FNA of 1112 nodules Nondx 9.7% Benign 73% Malignant/suspicious for malignancy 9.3% FLUS/AUS or follicular neoplasm 8%--89 pts and offered GEC testing Afirma TM in action Mayo clinic 53 nodules with GEC results 13 (24%) BENIGN 4 (76%) SUSPICIOUS McIver 212 ATA abstract 89 AUS/FLUS/FN 53 with GEC results 3 not submitted (pt declined, MD choice) 6 NO result (insuff RNA) McIver ATA abstract surgery 13 no surgery 23 (85%) BENIGN 4 (15%) CANCER Afirma TM in action Mayo clinic Positive predictive value Mayo 14% vs. NEJM 38% Different cancer prevalence in FLUS/FN NEJM 25% vs. Mayo 15% Different proportion of GEC suspicious results in FLUS/FN NEJM 57-6% vs Mayo 78% Real world application may vary... NPV NPV and PPV for Afirma TM GEC based upon N Engl J Med : % 38% 9% Sensitivity and 52% Specificity Prevalence of malignancy PPV Courtesy of Bryan McIver Negative Predictive Value falls at higher disease prevalence NPV % Sensitivity 9% Sensitivity 8% Sensitivity When do we use GEC testing at Penn? FLUS/AUS Follicular/Hürthle cell neoplasm Cancer risk <25% Gene expression classifier HIGH NEGATIVE PREDICTIVE VALUE BENIGN SUSPICIOUS Prevalence of malignancy OBSERVE LOBECTOMY Courtesy of Bryan McIver 7
8 Molecular Analysis Oncogene testing identifies indeterminate nodules with a high risk of malignancy Used for patients undergoing surgery Suspicious for PTC, suspicious nodules with FN or non dx cytology and suspicious sonographic appearance m RNA Gene expression classifier has a high NPV Used when observation rather than surgery is the goal FLUS x 2, small FN, no suspicious US features Benign Malignant Nondx* Result reported Evaluation of thyroid nodules 212 History, physical examination, TSH Thyroid US with risk stratification for FNA FNA cytology sample Follicular lesion of undetermined significance Follicular/Hürthle cell neoplasm Suspicious for malignancy Molecular analysis Result reported To reflect back 5 years... New England Journal of Medicine 1964 Thank you 214 Ultrasound FNA Molecular analysis 8
Molecular Diagnostics in Thyroid Cancer
Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical
More informationConflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.
Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates Jeffrey F. Krane, MD PhD Associate Professor of Pathology Harvard Medical School Chief, Head and Neck Pathology Service Associate Director,
More informationBRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
More informationOverview 1/28/2013. Bethesda System Cytology Categories and Molecular Alterations in Thyroid FNA Specimens
Bethesda System Cytology Categories and Molecular Alterations in Thyroid FNA Specimens N. Paul Ohori, M.D. Department of Pathology University of Pittsburgh Medical Center Pittsburgh, Pennsylvania N. Paul
More informationMEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID EFFECTIVE DATE: 11/19/15
MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationApplication of Molecular Diagnosis: Present and Future
Application of Molecular Diagnosis: Present and Future Dong Jun Lim, MD., PhD. Associate Professor Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary s Hospital,
More informationWriting Group for the AACE Thyroid Scientific Committee. Bernet V, Hupart KH, Parangi S and Woeber KA
Molecular Diagnostic Testing of Thyroid Nodules with Indeterminate Cytopathology Summary Highlights Writing Group for the AACE Thyroid Scientific Committee Bernet V, Hupart KH, Parangi S and Woeber KA
More informationCorporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2015 Origination: 3/2013 Next Review: 3/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationName of Policy: Molecular Markers in Fine Needle Aspirates of the Thyroid
Name of Policy: Molecular Markers in Fine Needle Aspirates of the Thyroid Policy #: 516 Latest Review Date: June 2015 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule, benefits
More informationValidation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach
Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation
More informationMedical Policy Manual. Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid. Date of Origin: April 2013
Medical Policy Manual Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid Date of Origin: April 2013 Section: Genetic Testing Last Reviewed Date: December 2015 Policy No: 49 Effective Date:
More informationMolecular Pathogenesis of Thyroid Cancer
Introduction Thyroid cancer is the fastest growing cancer diagnosis in the US [1, 2] with a total of 44,670 new cases and 1,690 deaths expected in 2010 (www.cancer.gov/cancertopics/types/thyroid). From
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 4/1/2015 Most Recent Review Date (Revised): 11/24/2015 Effective Date: 2/1/2016 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationGENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE
Genomics in Medicine Series GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE Electron Kebebew, MD, FACS Outline To assess the change in thyroid cancer epidemiology
More informationClassificazioni citologiche: verso uno schema internazionale unificato?
Cytology and molecular biology for thyroid nodules diagnos6c categories to clinical ac6ons From Classificazioni citologiche: verso uno schema internazionale unificato? A. Crescenzi Diagnostic categories
More informationMolecular pathology of thyroid cancers
Molecular pathology of thyroid cancers Peter Lakatos 1st Department of Medicine Semmelweis University Thyroid nodules 4-7% of population with palpable nodules More frequent in women Incidence increasing
More informationIl percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare
Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Maria Chiara Zatelli Sezione di Endocrinologia Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
More informationThyroid Cancer Diagnosis and Management. Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010
Thyroid Cancer Diagnosis and Management Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010 DISCLOSURE NOTHING TO DISCLOSE in regard to financial conflict
More informationThyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules)
Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules) Jeffrey S. Freeman, D.O., F.A.C.O.I. Chairman, Division of Endocrinology and Metabolism Philadelphia College
More informationClassifying Your Thyroid FNA Specimens Using Bethesda Terminology: Use of Adjunct Molecular Reflex Testing
Classifying Your Thyroid FNA Specimens Using Bethesda Terminology: Use of Adjunct Molecular Reflex Testing Constantine Theoharis, MD Assistant Professor David Chhieng, MD, MBA, MSHI Professor Director
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationThyroid FNA Ancillary Studies. Douglas P. Clark, M.D. Zubair W. Baloch, M.D., Ph.D.
Thyroid FNA Ancillary Studies Douglas P. Clark, M.D. Zubair W. Baloch, M.D., Ph.D. What are the goals of ancillary studies of thyroid FNAs? Characterization of a known malignancy (
More informationD. N. Poller and S. Glaysher
DOI:10.1111/cyt.12109 BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy Department of
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationMolecular Diagnosis of Follicular Cell Nodules
Endocrine Pathology Society Companion Meeting USCAP 2015 Molecular Diagnosis of Follicular Cell Nodules Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical
More information<1 cm WDT-UMP, FT-UMP. Kakudo K et al, Pathol Int,2009, Endocr J, 2011 and Pathol Int, 2012
More information
330 Diagnostic Cytopathology, Vol 34, No 5 # 2006 WILEY-LISS, INC.
Does Hurthle Cell Lesion/Neoplasm Predict Malignancy More Than Follicular Lesion/Neoplasm on Thyroid Fine-Needle Aspiration? Robert T. Pu, M.D., Ph.D., 1 * Jack Yang, M.D., 2 Patricia G. Wasserman, M.D.,
More informationDIAGNOSTIC USE OF MOLECULAR MARKERS IN THE EVALUATION OF THYROID NODULES
Presented at the AACE Annual Meeting & Congress, May 23-27, 2012, Philadelphia, PA Review Article DIAGNOSTIC USE OF MOLECULAR MARKERS IN THE EVALUATION OF THYROID NODULES Matthew I. Kim, MD; Erik K. Alexander,
More informationThyroid Cancer A Multidisciplinary Approach
Thyroid Cancer A Multidisciplinary Approach Shuvendu Sen, MD, MS, FACP Associate Program Director, Internal Medicine Residency Program Director, Medical Education Raritan Bay Medical Center, Rutgers University
More informationThyroid cancer: In a flourish of subtypes, genes, and drivers
Thyroid cancer: In a flourish of subtypes, genes, and drivers Date : January 19, 2015 Karen Titus January 2015 Dark matter is shrinking at least in the thyroid cancer part of the universe. Until recently,
More informationStandardized interpretation of fine-needle aspiration
THYROID Volume 25, Number 7, 2015 ª Mary Ann Liebert, Inc., and the American Thyroid Association DOI: 10.1089/thy.2014.0502 American Thyroid Association Statement on Surgical Application of Molecular Profiling
More informationUpdate on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationBRAF as a prognostic marker in papillary thyroid cancer
12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia
More informationLatest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma
Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma April 2008 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor of Surgery and Medicine David Geffen School of
More informationSurgical Perspective of T1799A BRAF Mutation Diagnostic Value in Papillary Thyroid Carcinoma
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.31 RESEARCH ARTICLE Surgical Perspective of T1799A BRAF Mutation Diagnostic Value in Papillary Thyroid Carcinoma Bayu Brahma 1 *, Erwin Danil Yulian 2, Muchlis
More informationGuidance on the reporting of thyroid cytology specimens
Guidance on the reporting of thyroid cytology specimens Unique document number Document name G089 Guidance on the reporting of thyroid cytology specimens Version number 1 Produced by Date active November
More informationSomething Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
More informationKevin H. Hsu, MS, DO, Corrado Minimo MD, Seth Zwillenberg, MD
A Patient with Synchronous Follicular (Hurthle Cell), Papillary, and Medullary Thyroid Carcinomas: A Case Report with Literature Review on Possible Incidence and Pathogenesis Kevin H. Hsu, MS, DO, Corrado
More informationNew Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers
New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers Yuri E. Nikiforov 1#, Linwah Yip 2, Marina N. Nikiforova 1 1 Department of Pathology and Laboratory Medicine, University
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationAdvances in Differentiated Thyroid Cancer
Advances in Differentiated Thyroid Cancer Steven A. De Jong, M.D., FACS, FACE Professor and Vice Chair Clinical Affairs Department of Surgery Loyola University Medical Center Thyroid Cancer classification
More informationMACHINE LEARNING FROM CONCEPT TO CLINIC: RELIABLE DETECTION OF BRAF V600E DNA MUTATIONS IN THYROID NODULES USING HIGH-DIMENSIONAL RNA EXPRESSION DATA
MACHINE LEARNING FROM CONCEPT TO CLINIC: RELIABLE DETECTION OF BRAF V600E DNA MUTATIONS IN THYROID NODULES USING HIGH-DIMENSIONAL RNA EXPRESSION DATA JAMES DIGGANS 1, SU YEON KIM 1, ZHANZHI HU 1, DANIEL
More informationOncologist. The. Endocrinology. The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
The Oncologist Endocrinology The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer ADRIENNE L. MELCK, LINWAH YIP, SALLY E. CARTY University of Pittsburgh School of Medicine, Section
More informationGenetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications
Open Access GENETIC TESTING IN DTC PATIENTS Rambam Maimonides Medical Journal Special Issue on Differentiated Thyroid Carcinoma Guest Editors: Ziv Gil, M.D., Ph.D. and Sagit Zolotov, M.D. Genetic Testing
More informationMOLECULAR REFLEX TESTING OF THYROID FNA
MOLECULAR REFLEX TESTING OF THYROID FNA Yuri E. Nikiforov, M.D., Ph.D. Division of Molecular Anatomic Pathology University of Pittsburgh School of Medicine FNA cytology is the most reliable diagnostic
More informationLocoregional recurrence or persistence of papillary carcinoma: radioiodine treatment
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico
More informationATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA
Papillary carcinoma is the most common of thyroid malignancies and occurs in all age groups but particularly in women under 45 years of age. There is a high rate of cervical metastatic disease and yet
More informationThyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD
Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,
More informationEvaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003
Evaluation and Management of the Breast Mass Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Common Presentations of Breast Disease Breast Mass Abnormal
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationGENE EXPRESSION TESTS
MEDICAL POLICY GENE EXPRESSION TESTS Policy Number: 2016T0552G Effective Date: January 1, 2016 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE APPLICABLE CODES.. DESCRIPTION OF SERVICES...
More informationThyroid Cancer. What is cancer?
What is cancer? Thyroid Cancer The body is made up of hundreds of millions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly fashion. During the early years of a
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationNicole Kounalakis, MD
Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations
More informationThyroid Cancer. What is thyroid cancer? The thyroid gland
Thyroid Cancer What is thyroid cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas of the body.
More informationThyroid and Adrenal Gland
Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More information2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
THYROID Volume 26, Number 1, 2016 ª American Thyroid Association ª Mary Ann Liebert, Inc. DOI: 10.1089/thy.2015.0020 SPECIAL ARTICLE 2015 American Thyroid Association Management Guidelines for Adult Patients
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationRADIATION INDUCED THYROID CANCER: FUNDAMENTAL AND APPLIED ASPECTS
2 Experimental Oncology 32, 2 24, 21 (September) Exp Oncol 21 32, 3, 2 24 RADIATION INDUCED THYROID CANCER: FUNDAMENTAL AND APPLIED ASPECTS M. Tronko 1,*, T. Bogdava 1, L. Voskoboynyk 1, L. Zurnadzhy 1,
More informationHistologic Subtypes of Renal Cell Carcinoma
Histologic Subtypes of Renal Cell Carcinoma M. Scott Lucia, MD Associate Professor Chief of Genitourinary and Renal Pathology Director, Prostate Diagnostic Laboratory Dept. of Pathology University of Colorado
More informationPolyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1
Course AP104 Endometrial Hyperplasia A morphologic Definition Hyperplasias Hormonal Effect or Precancer? George L. Mutter, MD Harvard Medical School and Brigham and Women s Hospital Boston, MA Endometrial
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationSonographic Findings in the Surgical Bed After Thyroidectomy
Article Sonographic Findings in the Surgical Bed After Thyroidectomy Comparison of Recurrent Tumors and Nonrecurrent Lesions Jung Hee Shin, MD, Boo-Kyung Han, MD, Eun Young Ko, MD, Seok Seon Kang, MD Objective.
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationAACE Advances in Medical and Surgical Management of Thyroid Cancer, 2015. Tampa, Florida.
AACE Advances in Medical and Surgical Management of Thyroid Cancer, 2015. Tampa, Florida. Dev Abraham MD, MRCP (UK), ECNU Professor of Medicine, Division of Endocrinology, Huntsman Cancer Institute, University
More informationIntroduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
More informationThe epidemic of thyroid cancer and its evolving management: Is less more?
The epidemic of thyroid cancer and its evolving management: Is less more? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine Surgery, and Leader, Endocrine Neoplasia
More informationRevised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
THYROID Volume 19, Number 11, 2009 ª Mary Ann Liebert, Inc. DOI: 10.1089=thy.2009.0110 ORIGINAL STUDIES, REVIEWS, AND SCHOLARLY DIALOG THYROID CANCER AND NODULES Revised American Thyroid Association Management
More informationMolecular analysis of thyroid tumors
S34 & 2011 USCAP, Inc. All rights reserved 0893-3952/11 $32.00 Molecular analysis of thyroid tumors Yuri E Nikiforov Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center,
More informationWhat is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More informationWELL DIFFERENTIATED THYROID CANCER
Scandinavian Journal of Surgery 93: 261 271, 2004 WELL DIFFERENTIATED THYROID CANCER N. R. Caron, O. H. Clark Department of Surgery, University of California, San Francisco and UCSF Comprehensive Cancer
More informationScreening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
More informationThe incidence of thyroid cancer has increased exponentially over
FEATURE THYROID Papillary thyroid cancer: the most common endocrine malignancy JAMES C. LEE FRACS STANLEY B. SIDHU FRACS, PhD Papillary thyroid cancer has an excellent prognosis and over 90% of affected
More informationPrediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma
Clinical Endocrinology (2014) 81, 282 288 doi: 10.1111/cen.12417 ORIGINAL ARTICLE Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma Yinlong Yang*,, Chengze Chen,
More informationRenal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationRenal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
More informationIncidence of Incidental Thyroid Nodules on Computed Tomography (CT) Scan of the Chest Performed for Reasons Other than Thyroid Disease
International Journal of Clinical Medicine, 2011, 2, 264-268 doi:10.4236/ijcm.2011.23042 Published Online July 2011 (http://www.scirp.org/journal/ijcm) Incidence of Incidental Thyroid Nodules on Computed
More informationFrozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationThyroid Biopsy Specialists An Innovative Role for Radiology Assistant
Thyroid Biopsy Specialists An Innovative Role for Radiology Assistant Ghai S, Atri M, Bret PM, Menezes R, Jia Y, Maan KA, Javed W, Boci R Sangeet Ghai, MD, FRCR Abdominal Imaging Assistant Professor, Faculty
More informationBreast Fine Needle Aspiration Cytology Reporting : A Study of Application of Probabilistic Approach
54 Original Study Indian Medical Gazette FEBRUARY 2013 Breast Fine Needle Aspiration Cytology Reporting : A Study of Application of Probabilistic Approach Amrish N. Pandya, Professor & Head, IHBT Department,
More informationENDOCRINE PATHOLOGY. Histological Evaluation of Thyroid Lesions by a Scanning Acoustic Microscope
S43 AP06-PP-000 ENDOCRINE PATHOLOGY Free Paper (Poster) Histological Evaluation of Thyroid Lesions by a Scanning Acoustic Microscope Katsutoshi Miura Basic Nursing, Hamamatsu University School of Medicine,
More informationManagement of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed
Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed Medical Grand Rounds December 10,2015 Christine Signore, MD ECNU Learning Objectives Discuss the epidemiology
More informationCystic Neoplasms of the Pancreas: A multidisciplinary approach to the prevention and early detection of invasive pancreatic cancer.
This lecture is drawn from the continuing medical education program Finding Hope: Prevention, Early Detection and Treatment of Pancreatic Cancer, Nov, 2011. Robert P. Jury, MD Cystic Neoplasms of the Pancreas:
More informationThyroid Gland Disease. Zdeněk Fryšák 3rd Clinic of Internal Medicine Nephrology-Rheumatology-Endocrinology Faculty Hospital Olomouc
Thyroid Gland Disease Zdeněk Fryšák 3rd Clinic of Internal Medicine Nephrology-Rheumatology-Endocrinology Faculty Hospital Olomouc t 1/2 = 5-7d t 1/2 = < 24 hrs Normal Daily Thyroid Secretion Rate:
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationAdvances in Diagnostic and Molecular Testing in Prostate Cancer
Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures
More informationS446 MOLECULAR-GENETIC CHARACTERISTICS OF THYROID TUMORS
S446 MOLECULAR-GENETIC CHARACTERISTICS OF THYROID TUMORS S. Shevchenko, L. Mostovich, N. Kolesnikov, L. Gulyaeva; MBIH Novosibirsk Clinical Hospital No.1, Institute of Molecular Biology and Biophysics
More informationCharacteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET
Characteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET Lorenzo Falchi, Long Trinh, Edith M Marom, Mylene Truong, Ellen J Schlette,
More informationAthyroid nodule is a palpable
PRACTICAL THERAPEUTICS Thyroid Nodules MARY JO WELKER, M.D., and DIANE ORLOV, M.S., C.N.P. Ohio State University College of Medicine and Public Health, Columbus, Ohio Palpable thyroid nodules occur in
More informationHemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma
1412 Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma XIAOLONG LI 1*, CUI ZHAO 1*, DANDAN HU 1, YANG YU 1, JIN GAO 2, WENCHUAN
More informationPeter M. Sadow & Michael C. Heinrich & Christopher L. Corless & Jonathan A. Fletcher & Vânia Nosé
DOI 10.1007/s12022-009-9101-3 Absence of BRAF, NRAS, KRAS, HRAS Mutations, and RET/ PTC Gene Rearrangements Distinguishes Dominant Nodules in Hashimoto Thyroiditis from Papillary Thyroid Carcinomas Peter
More informationThyroid Fine-Needle Aspiration Indications and Technique. Subcommittee members Zubair W. Baloch, MD, PhD Martha Bishop Pitman, MD
Thyroid Fine-Needle Aspiration Indications and Technique Subcommittee members Zubair W. Baloch, MD, PhD Martha Bishop Pitman, MD Thyroid FNA Indication Clinical Thyroid Nodule (s) > 1 cm? Hypo-functioning
More informationPredictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI)
Predictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI) D.A. Pizzuto1, S. Annunziata1, C. Brunelli2, G. Perotti1,
More informationMultiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules KIDNEY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More information